Read about pancreatic cancer new types, causes, treatment, prognosis, life expectancy, stages, drugs, and diagnosis. Learn about pancreatic cancer survival rates. Pancreatic cancer symptoms and signs often do not manifest until the cancer has metastasized.
Phosphofructokinase (PFK) is a glycolytic enzyme that catalyzes the irreversible transfer of a phosphate from ATP to fructose-6-phosphate: fructose-6-phosphate + ATP fructose-1,6-bisphosphate + ADP.In part because of the irreversible nature of this step in glycolysis, PFK is the key regulatory enzyme for glycolysis.When ATP levels are high in the cell, the cell no longer needs metabolic energy production to occur.In this case, PFK's activity is inhibited by allosteric regulation by ATP itself, closing the valve on the flow of carbohydrates through glycolysis.Recall that allosteric regulators bind to a different site on the enzyme than the active (catalytic) site.hen ATP levels are high in the cell, the cell no longer needs metabolic energy production to occur. In this case, PFK's activity is inhibited by allosteric regulation by ATP itself, closing the valve on the flow of carbohydrates through glycolysis.
A recent study provided evidence that the intracellular protein FKBP38 is an endogenous inhibitor of mTORC1 [ 46 ]. FKBP38 bound to the FRB domain of mTOR and inhibited its activity in vitro, similar to FKPB12/rapamycin.se of rapamycin plus an inhibitor of Akt or PI3K is one way to circumvent this problem, and another is to use a dual-specificity agent such as PI-103 that targets both PI3K and mTOR. Another strategy is to develop drugs that selectively target the mTOR kinase domain, which should inhibit both mTORC1 and mTORC2.